Strides Pharma Science Results Update

Strides Pharma Science Management Change

Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.

Execution

Five-year term effective November 1, 2026

Strides Pharma Science Employee Stock Options

Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.

Strides Pharma Science Investor Presentation: Key Takeaways

Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.

Strides Pharma Science Results Update

Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.

Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY

Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.

Key figure

Net profit ₹134.1 Cr · +2.0% YoY

Strides Pharma Science Board Meeting Date

Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.

CARE Ratings Results Update

CARE Ratings reported strong Q2 and H1 FY27 operating income and profit growth. The board also declared an interim dividend of Rs 10 per share.

EPACK Durables Results Update

EPACK Durable reported record first-half revenue and strong Q2 FY27 growth. The board also approved exiting its EPAVO joint venture stake.

3i Infotech Results Update

3i Infotech reported Q2FY27 revenue of Rs.182.0 crore, up 4.1% year-on-year. Quarterly PAT stood at Rs.6.7 crore and 25 new client wins were added.

Suryoday Small Finance Bank Results Update

Suryoday Small Finance Bank released a press release on its unaudited Q2 and H1 FY27 results. The release highlights profit after tax of Rs.151.7 Cr for H1 FY27, up 131% year on year.

Indegene Results Update

Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.

Kalpataru Results Update

Kalpataru's Q2 FY27 revenue was Rs.437 Crore with a Rs.71 Crore PAT loss. Pre-sales fell 5% year-on-year, while collections stayed flat.